MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety
Allergy and Asthma Proceedings, 07/30/2012
Meltzer EO et al. – MP29–02 significantly improved reflective total ocular symptom score (rTOSS) compared with placebo, provided a clinically important improvement in the overall RQLQ score, and was well tolerated. In this study, MP29–02 provided more complete symptom relief than two widely used first–line allergic rhinitis (AR) treatments and was well tolerated.